There are a couple of things. Luckily, we have had many fewer infections in the country and a bit of a delay with respect to the onset of the peak. That pushes us out a little further from the U.S. Also, people could donate plasma post-infection and it could be transfused back into potential recipients. One of the challenges in that is that, despite the potentially hundreds to thousands of different systems in the U.S. where that's been done, I would say that they've learned probably very little from the experience. They can't probably say that the treatment is better than not giving the treatment. Really, the only way to test this, to know for the next thousand patients, is to be able to compare it to the standard of care in a similar group of people.
That's what that study is trying to do, and I think that's the right approach.